Phase II Study of Cadonilimab Combined with Paclitaxel, Cisplatin, and Radiation Therapy for Treating Recurrent and Oligometastatic Endometrial Cancer in Women

What this Trial Is About

Researchers are evaluating the combination of cadonilimab with paclitaxel, cisplatin, and radiation therapy for women with locally recurrent and oligometastatic endometrial carcinoma. This phase II trial aims to assess the treatments impact on overall response rate, progression-free survival, disease control rate, overall survival, and safety. It also seeks to identify biomarkers that may help guide the use of immune-oncology drugs in this combination therapy. Participants will receive intravenous infusions of cadonilimab every three weeks for up to 24 months or until certain conditions occur. Chemotherapy with paclitaxel and cisplatin is given every three weeks for 6 to 8 cycles, with alternatives available if needed. Radiation therapy will target all tumor lesions, including original sites and metastases, using various techniques and doses, typically starting after initial systemic therapy cycles. Throughout the study, participants will have regular clinic visits for checkups, scans, and blood and tissue sample collection to monitor treatment effects and safety. Researchers will track progression-free survival over up to 60 months and assess response rates, overall survival, disease control, and adverse events over about two years. The study includes careful monitoring and biomarker analysis to better understand treatment outcomes.

Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma